GxP-Compliant Bioanalytical Support for Pivotal Trials
Executing these long-term studies requires a robust bioanalytical framework. Franklin Biolabs develops and validates sensitive, product-specific qPCR assays under GxP conditions to support pivotal clinical trials. Our >100,000 sq ft facility is equipped to handle high-throughput sample analysis, ensuring data integrity and timely reporting for programs targeting IND submission within 18-24 months.
)
Our approach is built on deep scientific expertise and a collaborative model that aligns with the specific objectives of your clinical program. This commitment to partnership ensures that the bioanalytical strategy is scientifically sound and regulatory-compliant from the outset.
“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner